Judge upholds Amgen’s Enbrel patents

You are here: Home > Biotech > Current Article

By Staff Report / Wednesday, July 1st, 2020 / Comments Off on Judge upholds Amgen’s Enbrel patents

Tri-county biotech heavyweight Amgen shot up more than 8 percent July 1 on news that it had successfully defended patents on bestselling rheumatoid arthritis drug Enbrel in a court contest with competitor Sandoz.  Shares of Thousand Oaks-based Amgen hit a new 52-week high and closed at $255.12.  The decision by the U.S. Court of Appeals…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.